Core Viewpoint - Quantum BioPharma Ltd. has reported significant progress in its financial and operational results for the year ended December 31, 2025, highlighting a strong balance sheet, reduced operating expenses, and advancements in its drug candidates, particularly Lucid-21-302 for multiple sclerosis and the dietary supplement unbuzzd [2][3][6][12]. Financial Performance - As of the date of filing, the company has $11.3 million USD in cash and digital assets, which is expected to sustain operations beyond January 2028 [2][14]. - Operating expenses decreased to $15.3 million USD in 2025 from $16.1 million USD in 2024, marking an improvement of approximately 5% [3]. - External research and development fees fell to $2.8 million USD in 2025 from $6.1 million USD in 2024 due to the completion of phase 1 clinical trials and R&D tax credits [4]. Operational Highlights - The company has successfully completed phase 1 oral toxicity studies for its multiple sclerosis drug candidate Lucid-21-302, showing no toxicity or significant side effects [6]. - A peer-reviewed journal published positive results from the clinical trial of the dietary supplement unbuzzd, which demonstrated its effectiveness in reducing blood alcohol concentration and hangover symptoms [5][7]. - Health Canada granted a product license for Quantum's natural health product Qlarity, allowing it to be sold in Canada [7]. Corporate Developments - Quantum BioPharma has made significant strides in capital market access, securing financing through various sources, including convertible debt and institutional loans [2]. - The company is preparing for a possible Initial Public Offering (IPO) for unbuzzd and has launched a Regulation D 506(c) offering to raise up to $5.0 million USD [7][15]. - The company is involved in a lawsuit against CIBC and RBC regarding alleged stock market manipulation, with ongoing court proceedings [8]. Future Outlook - The company is focused on advancing its drug candidates, particularly Lucid-21-302, with plans for a Phase 2 trial and further development of its product pipeline targeting neurodegenerative and metabolic disorders [12][13]. - Management expresses confidence in maintaining a strong financial position and operational efficiency moving forward [11][15].

Summary of Immunic's Conference Call Company Overview - **Company**: Immunic - **Product**: Vidofludimus calcium - **Focus**: Treatment for multiple sclerosis (MS) Key Points Unique Mechanism of Action - Vidofludimus calcium activates Nurr1, a nuclear receptor involved in neuroprotection, which differentiates it from other MS treatments [4][7] - It also acts as a DHODH inhibitor, providing an established anti-inflammatory mechanism [4][7] Clinical Data and Efficacy - The EMPHASIS study showed: - 76% reduction in cumulative active lesions - 78% reduction in gadolinium-enhancing lesions [20] - A numerical reduction of disability progression (CDW) by over 50% in the phase 2 study [14] - Safety and tolerability were comparable to placebo, indicating a favorable profile [21] Comparison with Other Treatments - Current oral therapies show efficacy rates of 30%-50% for glatiramer acetate and Aubagio, while anti-CD20 therapies show 80%-90% [22][24] - Vidofludimus calcium aims to provide a better benefit-risk profile, especially for patients who cannot tolerate existing therapies [43] Market Opportunity - The oral therapy market represents 35%-40% of total prescriptions for MS [77] - An estimated 5%-10% of patients on anti-CD20 therapies may need to switch due to serious infections, representing a potential $1 billion market in the U.S. alone [80][81] - The average cost of branded oral therapies is projected to be around $120,000 WAC at launch [85] Phase 3 Studies - The ENSURE studies for relapsing MS are fully enrolled, with primary endpoints focused on time to first relapse and secondary endpoints including MRI biomarkers and disability progression [57][58] - Expected readout for the studies is at the end of the year [62] Progressive MS Treatment - Immunic is also targeting primary progressive MS (PPMS) with a phase 2 study showing a 31% reduction in disability progression [112][113] - The potential market for PPMS is significant, with Roche's Ocrevus generating over $3 billion in sales from this segment [151] Safety Profile - Vidofludimus calcium has shown a clean safety profile with low rates of adverse events compared to existing therapies [46][48] - No significant liver enzyme changes were observed, differentiating it from other DHODH inhibitors [54] Future Outlook - Immunic plans to initiate pivotal studies for PPMS, with expectations of replicating positive data from previous studies [155] - The company believes it has a differentiated asset that could capture significant market share in both relapsing and progressive MS [161] Conclusion - Immunic is positioned to address unmet needs in the MS market with vidofludimus calcium, focusing on both relapsing and progressive forms of the disease, while emphasizing safety and tolerability as key differentiators [161]

Core Insights - TG Therapeutics, Inc. announced the schedule for presentations on BRIUMVI® (ublituximab-xiiy) data for patients with relapsing forms of multiple sclerosis (RMS) at the AAN 2026 annual meeting [1][2] Company Overview - TG Therapeutics is a biotechnology company focused on developing and commercializing treatments for B-cell diseases, with BRIUMVI® approved for treating adult patients with RMS in the U.S. and several other countries [27] Product Information - BRIUMVI is a monoclonal antibody targeting CD20-expressing B-cells, designed through glycoengineering to enhance B-cell depletion at lower doses [3] - The product is indicated for adults with RMS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease [4] Clinical Studies and Presentations - Upcoming presentations include data from the ENABLE Phase 4 observational study and updates from the ENHANCE study regarding the safety and tolerability of a modified dosing regimen [2][6] - The presentations will take place on April 21, 2026, during the AAN annual meeting [6] Safety Information - BRIUMVI has contraindications for patients with active Hepatitis B virus infection and a history of life-threatening infusion reactions [5][7] - Infusion reactions occurred in 48% of patients treated with BRIUMVI, with serious reactions in 0.6% of patients [5] - The overall infection rate in BRIUMVI-treated patients was 56%, with serious infections at 5% [9] Market Context - Relapsing multiple sclerosis (RMS) affects nearly 1 million people in the U.S., with approximately 85% initially diagnosed with relapsing-remitting multiple sclerosis [26]

Core Insights - Genentech announced that the pivotal Phase III study (FENhance 1) of fenebrutinib in relapsing multiple sclerosis (RMS) met its primary endpoint, showing a 51% reduction in annualized relapse rate (ARR) compared to teriflunomide over at least 96 weeks of treatment [1][3] - The results from FENhance 1 are consistent with FENhance 2, which showed a 59% reduction in ARR, indicating a profound benefit on relapsing and progressive disease biology [1][3] - Secondary endpoints in both RMS studies demonstrated statistically significant reductions in brain lesions, with favorable trends observed in all progression endpoints for fenebrutinib [1][3] Study Details - FENhance 1 and 2 are Phase III multicenter, randomized, double-blind studies involving 1,497 adult patients with RMS, comparing fenebrutinib to teriflunomide [7] - Participants were randomized 1:1 to receive either oral fenebrutinib twice daily or oral teriflunomide once daily for at least 96 weeks [7] - The primary endpoint was ARR, while secondary endpoints included MRI lesion counts and measures of disability progression [8] Safety and Efficacy - Liver transaminase elevations in both RMS studies were comparable to teriflunomide, with one Hy's Law case reported in each treatment arm, both of which were asymptomatic and resolved after discontinuation [4] - A total of 1 fatal case was reported in the teriflunomide arm, while 8 fatal cases occurred in the fenebrutinib arms, with further analyses ongoing to understand these findings [5] - Fenebrutinib targets B cells and microglia to control acute inflammation and address chronic damage, designed to have high potency and selectivity [6][11][12] Future Developments - Full data from the FENhance 1 and 2 studies will be presented at the American Academy of Neurology (AAN) Annual Meeting in 2026 and submitted to regulatory authorities alongside data from the FENtrepid study [2]

Core Insights - Roche announced that the pivotal Phase III study (FENhance 1) of fenebrutinib in relapsing multiple sclerosis (RMS) met its primary endpoint, showing a 51% reduction in annualized relapse rate (ARR) compared to teriflunomide over at least 96 weeks of treatment [1][8] - The results from FENhance 1 are consistent with FENhance 2, which showed a 59% reduction in ARR, indicating a profound benefit on relapsing and progressive disease biology [1][3][8] - Secondary endpoints in both RMS studies demonstrated statistically significant reductions in brain lesions, with favorable trends observed in all progression endpoints for fenebrutinib [1][3] Study Details - FENhance 1 and 2 are Phase III multicenter, randomized, double-blind studies involving 1,497 adult patients with RMS, comparing fenebrutinib to teriflunomide [7] - Participants were randomized 1:1 to receive either oral fenebrutinib twice daily or oral teriflunomide once daily for at least 96 weeks [7] - The primary endpoint was ARR, while secondary endpoints included MRI lesion counts and confirmed disability progression [8][9] Safety Profile - Liver transaminase elevations in both RMS studies were comparable to teriflunomide, with one Hy's Law case reported in each treatment arm, both of which were asymptomatic and resolved after discontinuation [4] - In the FENhance studies, one fatal case was reported in the teriflunomide arm and eight in the fenebrutinib arms, with further analyses ongoing to understand these findings [5] Mechanism of Action - Fenebrutinib targets B cells and microglia, controlling acute inflammation and addressing chronic damage that drives long-term disability progression [6][11] - It is a non-covalent BTK inhibitor designed for high potency, selectivity, and reversibility, allowing it to cross the blood-brain barrier and target chronic inflammation [12] Future Plans - Full data from the FENhance 1 and 2 studies will be presented at the American Academy of Neurology (AAN) Annual Meeting 2026 and submitted to regulatory authorities alongside data from the FENtrepid study [2]

Core Insights - The company is experiencing significant growth in the BRIUMVI product line, with a total global revenue of approximately $616 million in 2025, primarily driven by U.S. net sales of $594 million, reflecting a 92% year-over-year growth [4][8][19] - The company is advancing its subcutaneous (subcu) BRIUMVI program, targeting a potential launch in 2028, which could simplify treatment for patients and expand the market opportunity [2][12][13] - Confidence in BRIUMVI is bolstered by clinical data showing nearly 90% of patients were free from confirmed disability progression after six years of treatment, with a low relapse rate [3][10] Financial Performance - The company reported a net income of $447.2 million for 2025, translating to $2.77 per diluted share, compared to $23.4 million or $0.15 per diluted share in 2024 [20] - Operating income for the year was $123 million, with total operating expenses of approximately $328 million, aligning with prior guidance [19][22] - The company has completed a $100 million share repurchase program and authorized an additional $100 million, reflecting confidence in its long-term outlook [5][21] Market Position and Strategy - BRIUMVI is gaining market share in the competitive IV anti-CD20 segment, with strong demand and increasing physician confidence [10][13] - The company is expanding its field organization to enhance coverage in high-opportunity areas and increase prescriber engagement [11][12] - The partnership with Christina Applegate for the Next In MS initiative aims to provide resources and support for individuals living with multiple sclerosis, enhancing the company's community engagement [12][51] Future Outlook - The company expects to generate U.S. BRIUMVI net revenue of $825 million to $850 million in 2026, with total global revenue projected at $875 million to $900 million [12][15] - Upcoming catalysts include pivotal data from the subcutaneous BRIUMVI program and updates from the ENHANCE trial, which aims to consolidate dosing schedules [52][53] - The company anticipates continued growth driven by expanding prescriber adoption and a growing patient base with strong persistence on therapy [13][15]

Financial Data and Key Metrics Changes - TG Therapeutics reported approximately $616 million in total global revenue for 2025, with $594 million coming from U.S. net sales of BRIUMVI, marking a 92% year-over-year growth and a 20% sequential growth from Q4 over Q3 [5][20] - The company achieved a net income of $447.2 million for the full year 2025, or $2.77 per diluted share, compared to $23.4 million, or $0.15 per diluted share in 2024 [23][24] Business Line Data and Key Metrics Changes - BRIUMVI U.S. net revenue reached $594 million for the full year, with Q4 net sales of $183 million, reflecting sustained momentum and growth driven by new patient starts and prescriber expansion [12][20] - Breyanzi continues to strengthen its position in the anti-CD20 market, with a balanced mix of treatment-naive and switch patients contributing to its growth [13][14] Market Data and Key Metrics Changes - The company expects U.S. Breyanzi net revenue guidance for 2026 to be between $825 million and $850 million, with total global revenue projected at $875 million to $900 million [16] - The first quarter of 2026 is expected to see U.S. revenue grow sequentially to approximately $185 million to $190 million, despite typical seasonal headwinds [17] Company Strategy and Development Direction - TG Therapeutics aims to maximize the multi-billion dollar BRIUMVI opportunity while expanding its pipeline judiciously for sustained future growth [9] - The company is developing a self-administered subcutaneous BRIUMVI, targeting pivotal top-line data later this year or early next year, with a potential 2028 launch [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued demand for BRIUMVI, citing strong patient persistence and physician confidence as key drivers [30][36] - The company anticipates generating positive cash flow in 2026 and beyond, providing financial flexibility within the biotech sector [9][24] Other Important Information - TG Therapeutics completed a $100 million share repurchase program and authorized an additional $100 million, reflecting confidence in the company's long-term outlook [10][24] - The partnership with Christina Applegate for the Next in MS initiative aims to provide resources and support for individuals living with MS, enhancing the company's presence in the community [11][15] Q&A Session Summary Question: Dynamics of sub-Q uptake in community practices - Management noted that they continue to gain shares in the IV segment, driven by clinical data and operational advantages, with no decrease in switches from Ocrevus to BRIUMVI [27][28] Question: Gross to net assumptions - Management indicated that gross to net can fluctuate, particularly in Q1 due to deductible resets, but this does not represent a structural change in their framework [31] Question: Proportion of new versus switch patients - Management confirmed record new patient enrollments and strong persistence, with repeat patients becoming a larger part of the business [34][36] Question: Incremental investments for sub-Q launch - Management stated that the overlap between the current field force for IV and sub-Q is about 80%, indicating minimal incremental costs for the sub-Q launch [46] Question: Market perspective on ENHANCE trial - Management believes that eliminating the second dose will enhance market share gains, as convenience is highly valued by both patients and centers [70][71]

Core Insights - TG Therapeutics reported total revenue of $192.6 million for Q4 2025 and $616.3 million for the full year, with BRIUMVI U.S. net revenue of $182.7 million and $594.1 million respectively [1][11] - The company targets approximately $875-900 million in total global revenue for 2026, including BRIUMVI U.S. net product revenue of approximately $825-850 million [1][13] Financial Performance - BRIUMVI U.S. net product revenue for Q4 2025 was $182.7 million, representing a 20% increase over Q3 2025, and $594.1 million for the full year 2025, reflecting a 92% year-over-year growth [6][13] - Total global revenue for 2025 was $616.3 million, with product revenue netting $606.9 million, compared to $313.7 million in 2024 [11][51] - The company achieved a net income of $23.0 million for Q4 2025 and $447.2 million for the full year, which includes a non-recurring income tax benefit of approximately $339.8 million [20][51] Clinical and Commercial Developments - BRIUMVI has seen significant growth in the U.S. market, supported by increasing adoption and expanding global availability, with approvals in multiple countries including the EU, UK, and Australia [2][6] - The company launched the "Next In MS" platform in collaboration with Christina Applegate to raise awareness of multiple sclerosis [3][6] - Updated data from clinical trials presented at the 2025 ECTRIMS meeting showed that 89.9% of patients with relapsing forms of multiple sclerosis were free from confirmed disability progression after six years of BRIUMVI treatment [6] Research and Development - Total R&D expenses for Q4 2025 were approximately $41.2 million, up from $23.9 million in Q4 2024, primarily due to increased manufacturing and clinical trial costs [20][51] - The company completed patient enrollment in several pivotal programs, including the Phase 3 trial for subcutaneous ublituximab and the ENHANCE trial evaluating a consolidated dosing regimen for intravenous BRIUMVI [12][20] Shareholder Returns - TG Therapeutics completed a $100 million share repurchase program in Q3 2025, purchasing approximately 3.5 million shares at an average price of $28.55 per share, and announced a new program to repurchase an additional $100 million of common stock [8]

Immunic Therapeutics Developing Selective Oral Therapies in Immunology NASDAQ: IMUX | February 2026 Cautionary Note Regarding Forward-Looking Statements This presentation contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These include statements regarding management's intentions, plans, beliefs, e ...

Core Insights - Roche announced that fenebrutinib, an investigational BTK inhibitor, met its primary endpoint of non-inferiority compared to OCREVUS in reducing disability progression in patients with primary progressive multiple sclerosis (PPMS), showing a 12% reduction in risk [1][5][6] Group 1: Study Results - The Phase III FENtrepid study involved 985 adult patients with PPMS, comparing daily oral fenebrutinib to intravenous OCREVUS for at least 120 weeks [7][12] - Fenebrutinib demonstrated a consistent treatment effect on the composite confirmed disability progression (cCDP12) across various patient subgroups, with curves separating as early as 24 weeks [1][2] - A post-hoc analysis indicated fenebrutinib was superior to OCREVUS on a composite endpoint, showing a 22% reduction in risk [3] Group 2: Treatment Effects - The strongest treatment effect was observed on the nine-hole peg test (9HPT), with a 26% reduction in the risk of worsening compared to OCREVUS [2] - Fenebrutinib showed a consistent clinical benefit in upper limb function, which is crucial for maintaining independence [3] Group 3: Safety Profile - Adverse events in the fenebrutinib group were comparable to OCREVUS, with infections occurring in 67.0% of patients on fenebrutinib versus 70.9% on OCREVUS [4] - Transient liver enzyme elevations were more frequent in the fenebrutinib group (13.3% vs 2.9% for OCREVUS), but all cases resolved after discontinuation [4] Group 4: Future Developments - Roche plans to submit regulatory applications for fenebrutinib in both PPMS and relapsing multiple sclerosis (RMS) following the readout of the second pivotal RMS study, FENhance 1, expected in mid-2026 [5][6]